Physician profile
Mislen Bauer
NPI 1447295217
$28,592.86
in general payments reported to CMS, 2019-2025
17 companies · $4,819 in 2025
The $4,819 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.17 · 2020: $7,545 · 2021: $114 · 2022: $3,477 · 2023: $9,400 · 2024: $3,223 · 2025: $4,819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Travel and Lodging: $4,992 · Food and Beverage: $2,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,220.00 |
| Travel and Lodging | $4,992.30 |
| Food and Beverage | $2,229.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $18,795.57 | 2021-2025 | Voxzogo 1.2mg, Palynziq |
| Astrazeneca Pharmaceuticals Lp | $7,519.69 | 2020 | |
| Alexion Pharmaceuticals, INC. | $1,328.88 | 2020-2025 | Koselugo, Strensiq |
| Ns Pharma, INC. | $294.28 | 2023 | Viltepso |
| Genzyme Corporation | $201.70 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.51 | 2023-2025 | Vpriv |
| Springworks Therapeutics, INC. | $75.97 | 2025 | Gomekli, Ogsiveo |
| Ipsen Biopharmaceuticals, INC | $56.56 | 2023 | Bylvay, Sohonos |
| Kyowa Kirin, INC. | $52.35 | 2024 | Crysvita |
| Ptc Therapeutics, INC. | $33.64 | 2025 | Sephience |
| Alnylam Pharmaceuticals INC. | $28.22 | 2025 | Oxlumo |
| Pharming Healthcare, INC. | $28.06 | 2024 | Ruconest |
| Mirum Pharmaceuticals, INC. | $24.96 | 2024 | Cholbam |
| Mauna Kea Technologies, INC. | $24.05 | 2025 | |
| Biogen, INC. | $22.26 | 2024 | Skyclarys |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Soleno Therapeutics, INC. | $21.59 | 2025 | Vykat Xr |
| Travere Therapeutics, INC. | $5.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mislen Bauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.